What tests would you perform to confirm your diagnosis?
4. What is the mechanism of hypoxemia in this patient?
The patient's trachea was successfully intubated, and mechanical ventilation was begun. 500 ml of Lactated Ringers were administered over 15 minutes. A chest X-ray was performed, and a complete blood count, coagulation panel, arterial blood gas (ABG) and a bilateral upper and lower extremity duplex ultrasonography were ordered. 5 . The ABG showed: PH7.32/ PaCO2 35 mm Hg/ PaO2 58/ Hco3 23/-1 (FIO2= 1). Interpret these results. Provide a differential diagnosis. 6 . Discuss the utility of obtaining an EKG in this patient's management. 7 . If troponin levels were drawn in this case, predict what they might be.
8. An echocardiogram is ordered and shows a right ventricular transverse diameter that is equal to left ventricular transverse diameter. What is your interpretation? 9. Serum creatinine rises to 2.2 mg/dl; discuss the utility of ordering a CT angiography (CTA) to rule out an acute PE under this circumstance. Indicate any further action, if any. Defend your answer. 10 . Would you start a thrombolytic on this patent? Why or why not? Defend your answer. 11 . What would be the indications of surgical pulmonary embolectomy in this case? 12 . What pressor would you choose to support the circulation pending definitive action? Your response should include a rationale that focuses on desired physiologic and pharmacologic effects. 13 . Discuss the utility of a pulmonary artery catheter to monitor pulmonary vascular pressures in this case.
14.
Pulmonary artery pressures were 52/38, mean 42 mm Hg, what would you do next? 15 . Discuss the utility of placing an inferior vena caval filter in this patient. Your response should include a rationale that focuses on the risks and benefits both short and long term.
16. Discuss the long-term anti-coagulation management of this patient. Your discussion should include the interaction between anti-coagulation and IVC filter.
17. The official diagnosis of this patient was 'submassive pulmonary embolism'. How different is 'submassive' from 'massive'? Are there any differences in management?
Model Discussion Content
Acute pulmonary embolism is a ubiquitous and potentially fatal condition in hospitalized patients. It is estimated that 600,000 episodes occur each year in the US resulting in 100,000 to 200,000 deaths [1] .
Pulmonary venous thrombo-embolism commonly arises from deep venous thrombi in the calf veins. The latter has the potential to propagate to more proximal veins including and above the popliteal veins from which, they are more likely to embolize [2] .
In acute PE, the mechanism of ventilation-perfusion mismatch is both mechanical; as a result of obstruction by the embolus and humoral; via the release of vasoactive mediators such as serotonin that lead to pulmonary arteriolar constriction with secondary right ventricular strain, dilatation, dysfunction and eventually failure [2] .
Diagnosing acute PE can be challenging since many common conditions in critically ill patients have similar clinical presentation. The differential diagnosis in our patient encompasses acute lung injury due to massive blood transfusion, pneumothorax secondary to central venous catheter placement, pulmonary edema secondary to acute myocardial infarction, new onset pneumonia as well as acute pulmonary embolism. Failure to timely diagnose and treat any of these conditions can lead to fatal consequences.
Multiple clinical scoring systems [3] (Table1) were developed in order to raise clinical suspicion of an acute PE. Based on Wells and Geneva clinical criteria [4] , our patient's criteria fit to a high probability of an acute PE: age older than 65, recent surgery, recent cancer, immobilization, presence of DVT, and tachycardia. The next step in diagnosing PE is to evaluate the patient for signs of hemodynamic instability (a systolic blood pressure 40 mmHg in the absence of other causes) [5] . Hemodynamically stable patients with a high clinical probability of PE should undergo a multi-detector computerized tomography (CT) to confirm the diagnosis. Patients who are too unstable to be transferred to a radiology suite to undergo a multi-detector CT should be immediately placed on therapeutic doses of intravenous heparin. They should then undergo an echocardiographic examination to check for right ventricular dysfunction suggestive of a PE-induced acute right ventricular pressure overload. Our patient was hemodynamically unstable based on his BP and he was not a suitable candidate to undergo a multidetector CT without a delay. Also, his serum creatinine was elevated, representing a relative contraindication for computerized tomographic angiography (CTA). Multidetector CT is 97% sensitive for the diagnosing PE [6] . Once the diagnosis is confirmed, an elective echocardiography should be performed to rule out signs of right ventricular dysfunction, which correlates with prognosis.
The third step in managing an acute PE is risk-stratification. It is crucial to distinguish between massive, sub-massive and non-massive PE since the prognosis and treatment vary drastically ( Table 2) . Patients with massive PE manifested by shock and sustained not otherwise-explained hypotension have a high mortality [7] and are candidates for both anticoagulation and thrombolysis [5] . Patients with non-massive pulmonary embolism are not in shock and show no signs of right ventricular strain or of myocardial necrosis. They are candidates for therapeutic anticoagulation only (thrombolysis not indicated) and have a lower mortality. Patients with submassive PE are those who are hemodynamically stable but have signs of right ventricular dysfunction or myocardial necrosis. The management of these patients is controversial in terms of whether to add thrombolysis to anticoagulation. Prognostically, signs of right ventricular dysfunction and myocardial necrosis are associated with poor prognosis. An S1, Q3, T3 pattern, a P-wave pulmonale, a right axis deviation and a right bundle-branch block, are all electrocardiographic signs of right ventricular dysfunction suggestive of massive rather than smaller pulmonary emboli. An increase in the diameter of the right ventricle in relation to that of the left ventricle predicts adverse short term outcomes in terms of in-hospital death, mortality at 30 days and at 3 months [8] . Elevated serum troponins are associated with a 9.4 times more risk of death from PE [9] . Therefore, serum troponins could be elevated in acute pulmonary embolism due to right ventricular myocardial necrosis that is not precipitated by an acute coronary syndrome.
Treatment of acute PE is both definitive and supportive. Definitive treatment entails therapeutic anticoagulation using either unfractionated or low molecular weight heparin. Compared to unfractionated heparin (UFH), low molecular weight heparin (LMWH) is associated with fewer incidences of embolic recurrence, less bleeding, and similar all-cause mortality in patients with non-massive PE [10] . Compared to UFH, LMWH has more predictable pharmacokinetics, does not require frequent monitoring, and is associated with less incidence of heparin-induced thrombocytopenia. Besides, LMWH has been shown to specifically decrease the risk of death in patients with DVT, compared to UFH [10] . Thrombolysis is reserved for patients with massive PE. Patients with submassive PE are a controversial group for using thrombolysis. Data from the recently completed EMPEROR trial [11] suggest that the mortality in patients with submassive PE treated with therapeutic anticoagulation is less than 3% with less additional mortality benefit from adjunctive thrombolysis. However, long-term outcomes in terms of right ventricular function and quality of life remain to be determined. Intravenous thrombolysis is associated with more rapid resolution of right ventricular dysfunction [12] . Hemodynamically unstable patients with contraindications for intravenous thrombolysis or with ineffective thrombolysis could be candidates for percutaneous thrombectomy or surgical embolectomy justified by the high mortality of hemodynamically unstable PE [13] . Surgical embolectomy may be performed off-cardiopulmonary bypass, with normo-thermia, and without cardioplegia or fibrillatory arrest. A hybrid procedure may be performed where catheter mechanical thrombectomy is combined with local infusion of thrombolytic agents such as tissue plasminogen activator. Hybrid techniques have been shown to improve the clinical success of mechanical thrombectomy [14] . Systemic thrombolysis increases the risk of bleeding and is mainly contraindicated in patients with intracranial disease, recent major surgery or trauma. The decision to proceed with surgical, catheter-based or hybrid procedures requires an interdisciplinary teamwork discussion, and should be performed in centers with facilities and expertise for such procedures.
Supportive treatment includes the use of inotropes and vasopressor to support cardiac function and to maintain peripheral tissue perfusion as well as mechanical ventilation to maintain oxygenation and ventilation. Placement of a pulmonary artery catheter (PAC) to monitor pulmonary artery pressures is not warranted, and may be risky in patients with acute PE. Placement of PAC may be associated with arrhythmias that may worsen the hemodynamic instability of patients in acute PE. Additionally, PAC carries the risk of dislodging a pulmonary embolus. Furthermore, information about pulmonary artery pressure and secondary right ventricular dysfunction can be obtained non-invasively by bedside echocardiography. An ino-dilator such as milrinone would be an ideal drug to start in this situation. Milrinone is a phosphodiesterase-3 inhibitor that prevents the breakdown of the enzyme adenyl cyclase-the enzyme that catalyzes the formation of cyclic adenosine monophosphate (cAMP) -thus increases intracellular calcium and hence cardiac inotropy. An increase in vascular smooth muscle c-AMP produces pulmonary and systemic vasodilation. It should be emphasized, however, that milrinone may be associated with systemic hypotension by virtue of its severe vasodilation leading to a reduction in coronary perfusion pressure and worsening of right ventricular ischemia by not meeting the increased demand of the strained right ventricle. Therefore, adding a vasopressor may be indicated to counter the severe vasodilator action of milrinone while maintaining its inotropic action.
Regarding vasopressors, vasopressin is more favorable than norepinephrine in the setting of elevated pulmonary artery pressure and secondary right ventricular failure. Vasopressin is not associated with an increase in the pulmonary vascular resistance, which could worsen right ventricular afterload. Selective pulmonary vasodilators such as inhaled prostacyclin could be used to produce pulmonary vasodilatation (via the production of cyclic adenosine monophosphate-cAMP) to lower PE-induced pulmonary hypertension. It also improves ventilation perfusion mismatch and hence improves gas exchange. It is less expensive and produces no toxic metabolites compared with nitric oxide [15] .
Insertion of IVC filters is reserved for patients with a contraindication to anticoagulation, for recurrent thromboembolism while on anticoagulation and for patients in whom a recurrent PE would be fatal [5] . Although IVC filters are effective in reducing the incidence of acute pulmonary embolism, they increase the incidence of subsequent deep vein thrombosis. It therefore important to resume anticoagulation once its contraindication has resolved. Patients with longterm contraindication anticoagulation qualify for a permanent IVC filter. Our patient qualifies for a permanent IVC filter because of his poor cardiopulmonary reserve and the possibility of a fatal consequence of a future PE. I propose a three-legged approach for the diagnosis and management of acute pulmonary embolism (Figure 1 ). 
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